controlled clinical trials in well-defined clinical popu lations. These trials will require the cooperation of clinical and basic scientists. At this time, preliminary and early clinical trials are in progress utilizing IL-i and TNF-a circulating inhibitors, IL-i receptor antag onists, and monoclonal antibodies to TNF-a and the TNF-a receptor.6' REFERENCES
More recently, other potential therapeutic agents have become available. Under specific physiologic condi tions, some of the cytokine receptors shed the extra cellular ligand-binding domain into the circulation.
Each of these â€oecirculating inhibitorsâ€• can bind its cytokine and prevent any biologic response to it. In addition to circulating inhibitors, cytokinelike molecules have been described. These molecules bind to the IL-i receptor, block IL-i binding, and are incapable of eliciting signal transduction.
In this review, we will examine the experimental evidence that supports the therapeutic use of three different types ofagents: antibodies, circulating inhib itors, and receptor antagonists ( Table 1 ). The potential of these inhibitors to serve as therapeutic agents awaits clarification. Although the biotechnology exists to support these human studies, careful, prospective, placebo-controlled randomized trials in well-defined groups of patients are necessary to precisely define any therapeutic value of these newer and more expen sive agents. It should be cautioned that these agents may have unexpected deleterious effects, since cyto kines appear to be important in tissue homeostatic and reparatory processes. Preliminary data indicate antibodies at least partially abrogates the in vivo effects of Gram-negative bacteremia. Furthermore, these preliminary data provide a fascinating suggestion that TNF-a increases the production of IL-6 and that IL-6 suppresses the production of TN F-a. The role of these endogenousagents in nature has not been defined, and to our knowledge there are no reports ofin vivo data which show that these circulating inhibitors can be used to treat Gram-negative sepsis in humans or animals. Yet there is enormous potential for these agents as specific cytokine blockers, and there is substantial in vitro evidence of efficacy.These inhibitors may also be important tools for deciphering the role ofa single cytokine during a complex multiple cytokine-mediated response, such as human sepsis syndrome.
RECEPTOR ANTAGONISTS

A receptor antagonist is a cytokinelike molecule
that can bind to a cytokine receptor but does not elicit a response. At the time of this publication, only an IL-i receptor antagonist has been described.@'51@â€• The IL-i receptor antagonist appears to be a distinct gene product that is highly homologous to IL-i and has been detected in nature . This molecule is biolog ically active in a recombinant form and can be used to block IL-i-mediated events. It is possible that receptor antagonistsexistin nature for other cytokines.
Seckingeret al@purified an IL-i inhibitor from
urine from febrile patients. The inhibitor had an apparent molecular weight of i8 to 25 kd and bound to the IL-iR. It completely blocked binding of authen tic IL-i. The action of this inhibitor appeared to be specific since it did not block the action of TNF-a. 
